Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment.

Neurobiology of Aging
Jonathan M SchottAlzheimer's Disease Neuroimaging Initiative investigators

Abstract

Cerebral atrophy rate is increasingly used as an outcome measure for Alzheimer's disease (AD) trials. We used the Alzheimer's disease Neuroimaging initiative (ADNI) dataset to assess if adjusting for baseline characteristics can reduce sample sizes. Controls (n = 199), patients with mild cognitive impairment (MCI) (n = 334) and AD (n = 144) had two MRI scans, 1-year apart; approximately 55% had baseline CSF tau, p-tau, and Abeta1-42. Whole brain (KN-BSI) and hippocampal (HMAPS-HBSI) atrophy rate, and ventricular expansion (VBSI) were calculated for each group; numbers required to power a placebo-controlled trial were estimated. Sample sizes per arm (80% power, 25% absolute rate reduction) for AD were (95% CI): brain atrophy = 81 (64,109), hippocampal atrophy = 88 (68,119), ventricular expansion = 118 (92,157); and for MCI: brain atrophy = 149 (122,188), hippocampal atrophy = 201 (160,262), ventricular expansion = 234 (191,295). To detect a 25% reduction relative to normal aging required increased sample sizes approximately 3-fold (AD), and approximately 5-fold (MCI). Disease severity and Abeta1-42 contributed significantly to atrophy rate variability. Adjusting for 11 predefined covariates reduced sample sizes by up to 30%. Tre...Continue Reading

References

May 1, 1997·Computer Methods and Programs in Biomedicine·P A FreeboroughR I Kitney
Apr 13, 2004·Lancet·Nick C Fox, Jonathan M Schott
Jul 15, 2004·IEEE Transactions on Medical Imaging·Simon K WarfieldWilliam M Wells
May 11, 2005·Neurology·N C FoxUNKNOWN AN1792(QS-21)-201 Study
Apr 25, 2007·Neurobiology of Aging·Clifford R JackUNKNOWN Members of the Alzheimer's Disease Cooperative Study (ADCS)
Nov 14, 2007·Journal of Clinical Epidemiology·George F BormWim A J G Lemmens
Aug 12, 2008·Neurobiology of Aging·Jasper D SluimerPhilip Scheltens
Apr 3, 2009·Brain : a Journal of Neurology·Clifford R JackUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 1, 2009·BMJ : British Medical Journal·Jonathan A C SterneJames R Carpenter
Aug 20, 2009·Current Alzheimer Research·Ronald C Petersen
Mar 17, 2010·NeuroImage·Kelvin K LeungUNKNOWN Alzheimer's Disease Neuroimaging Initiative

❮ Previous
Next ❯

Citations

Dec 1, 2012·Journal of Neural Transmission·C AnnweilerUNKNOWN WALK Team-Working group Angers-London for Knowledge
Oct 20, 2012·PloS One·Dominic HollandUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Apr 5, 2013·PloS One·K Abigail AndrewsUNKNOWN Australian Imaging Biomarkers, Lifestyle Flagship Study of Ageing
Jun 24, 2010·Neurobiology of Aging·Giovanni B Frisoni, Michael W Weiner
Mar 24, 2015·NeuroImage·Prashanthi VemuriUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Feb 1, 2011·NeuroImage·Kewei ChenUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Apr 14, 2012·NeuroImage·Lei YuanUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Nov 4, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael W WeinerUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Mar 26, 2013·Neurobiology of Aging·Josephine BarnesUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 22, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael W WeinerUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 22, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Clifford R JackMichael Weiner
May 13, 2015·NeuroImage·M LorenziUNKNOWN Alzheimer's Disease Neuroimaging Initiative (ADNI)
Dec 12, 2017·Journal of Alzheimer's Disease : JAD·Patrick G KehoeYoav Ben-Shlomo
Mar 24, 2018·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Zeng Jie YeHong Zhong Qiu
Feb 16, 2012·Clinical Trials : Journal of the Society for Clinical Trials·Walter T AmbrosiusNicholas M Pajewski
Oct 10, 2013·Clinical Pharmacology and Therapeutics·J Cummings, K Zhong
Jan 21, 2016·Annual Review of Public Health·Catherine M Crespi
Sep 25, 2015·Journal of Alzheimer's Disease : JAD·Manuel Menéndez-GonzálezOscar Arias-Carrión
Nov 11, 2017·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Daniela BertensPieter Jelle Visser
May 31, 2016·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Hossein Tabatabaei-JafariNicolas Cherbuin
Aug 13, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael W WeinerUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jun 16, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael W WeinerUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Sep 23, 2019·Journal of Neurology, Neurosurgery, and Psychiatry·Neil Sn Graham, David J Sharp
Dec 25, 2010·Annals of Neurology·Jonathan M SchottUNKNOWN Alzheimer's Disease Neuroimaging Initiative Investigators
Aug 11, 2011·Human Brain Mapping·Dominic HollandUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 7, 2019·Frontiers in Neurology·Muhammad MunirUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Oct 26, 2020·Brain : a Journal of Neurology·Neil S N GrahamDavid J Sharp
May 15, 2016·Psychiatry Research. Neuroimaging·Keith S CoverUNKNOWN Alzheimer's Disease Neuroimaging Initiative, neuGRID
Dec 27, 2019·NeuroImage·Ferran PradosClaudia Wheeler-Kingshott
Dec 13, 2018·Progress in Nuclear Magnetic Resonance Spectroscopy·Andrew M Blamire
Jul 4, 2021·Neurobiology of Aging·Oshin SanghaUNKNOWN Australian Imaging Biomarkers and Lifestyle flagship study of ageing

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.